 |
|
|
|
|
|
|
|
|
|
|
|
1 to 7 of 7 results |
|
 |
|
|
|
|
|
 |
|
|
|
|
Lee V. on PAPER: Fauvet B. et al., 2012, Our experience working with α-synuclein is similar to Lashuel and colleagues’ in that we always... 17 Feb 2012.
|
|
|
 |
|
|
Lee V, Trojanowski J. on LIVE DISCUSSION: Mice on Trial? Issues in the Design of Drug Studies, Picking the Right Model of Neurodegeneration for Drug Discovery for Patients With Sporadic... 27 May 2008.
|
|
|
|
|
|
Lee V, Trojanowski J. on NEWS: Axonal Transport Not Bothered by Tau Elevation In Vivo,
In this paper, Yuan et al. report elegant studies of axonal transport in vivo using tau... 14 Feb 2008.
|
|
|
|
|
|
Lee V, Trojanowski J. on NEWS: Birds of a Feather…Mutations in Tau Gene Neighbor Progranulin Cause FTD, These studies are spectacular advances in FTD research that open up new avenues for... 17 Jul 2006.
|
|
|
|
|
|
Lee V. on PAPER: Panneerselvam S. et al., 2006, The Mandelkows have managed to decipher the x-ray crystallographic structure of the part of... 15 Feb 2006.
|
|
|
|
|
|
Lee V, Trojanowski J. on PAPER: Aarsland D. et al., 2003, This paper demonstrates a much higher incidence of dementia in PD patients than previously... 30 Apr 2003.
|
|
|
|
|
|
Lee V, Trojanowski J. on NEWS: Tau and α-synuclein at the Nexus of Alzheimer's and Parkinson's, The Wilson et al. paper is relevant to the findings in our paper. While the authors do not... 29 Apr 2003.
|
|
|
|
|
|
|
1 to 7 of 7 results |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
The ALS Forum is a web-based collaborative effort to bring together valuable ALS-related resources for use by researchers worldwide in both academia and industry-based settings.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Should the FDA be allowed to use data from overseas clinical trials? |
|
|
|
|
|
|
|
|
|
|
|
Absolutely, we are running out of viable subjects in the U.S. |
|
|
|
|
|
|
 9 |
|
|
|
|
|
|
|
|
|
|
|
Yes, so long as the data is reliable |
|
|
|
|
|
|
31 |
|
|
|
|
|
|
|
|
|
|
|
No, the trials are not as rigorous |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
No, the data should be repeated in the U.S. |
|
|
|
|
|
|
5 |
|
|
|
|
|
|
|
|
|
|
|
No, the drug sponsors are just trying to cut corners |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
Responses: 51 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
Archived Polls |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
 Antibodies
Cell Lines
Collaborators
Papers
Research Participants
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Home
See our latest Webinar: 
